about
Characterization of Diabetogenic CD8+ T Cells: IMMUNE THERAPY WITH METABOLIC BLOCKADE.The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus.Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA in New-Onset Type 1 DiabetesA Call for Improved Reporting of Human Islet Characteristics in Research ArticlesStrength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet ExperienceCollateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint InhibitorsIntroducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 DiabetesStandardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent AdvancesLow-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data
P50
Q36987677-901EC964-870D-4A82-AF6E-40C07D1BDDE9Q42371925-D3C46166-D581-4698-96A4-71D4EDED600FQ57163295-90AF599B-8FFC-4BD5-8876-0B043913CC19Q60491892-806422D7-BC5A-40EE-90F0-EF6107133C7CQ88697599-AB307046-B06E-4433-9C6E-11389DE1CD3FQ89224295-05200A76-A8F9-4F0C-8387-5D6031187F0DQ91385263-A69B6C01-87D0-41AC-928C-5279B5D169D0Q92917051-D7712B1F-2613-4C75-A4A1-8DDAEB4C6B82Q92985801-2BD274E3-C594-47D4-ADF6-3C556150F8DA
P50
description
investigador
@es
researcher
@en
name
Kevan C Herold
@en
type
label
Kevan C Herold
@en
prefLabel
Kevan C Herold
@en
P108
P31
P496
0000-0003-1534-6613